Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$39.99 +2.0%	$33.35	$23.42 ▼ $62.58	$2.27B	0.73	654,758 shs	628,785 shs
CGON CG Oncology	$26.08 +4.5%	$25.96	$14.80 ▼ $40.47	$1.90B	0.86	857,904 shs	628,134 shs
KNSA Kiniksa Pharmaceuticals International	$28.42 +1.2%	$27.80	$17.82 ▼ $30.69	$2.05B	0.05	555,224 shs	339,739 shs
OPT Opthea	$3.41 +7.2%	$3.41	$2.02 ▼ $6.30	$524.84M	1.17	27,295 shs	3,000 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+2.04%	+2.35%	+11.86%	+44.58%	-16.77%
CGON CG Oncology	+4.53%	-3.55%	+2.44%	+26.36%	-30.73%
KNSA Kiniksa Pharmaceuticals International	+1.17%	-1.32%	+0.04%	+40.62%	+27.16%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+60.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3958 of 5 stars	3.4	3.0	4.3	2.4	0.8	1.9
CGON CG Oncology	2.491 of 5 stars	4.5	1.0	0.0	2.7	0.8	0.0
KNSA Kiniksa Pharmaceuticals International	3.3433 of 5 stars	3.5	4.0	0.0	2.1	3.3	0.6
OPT Opthea	0.3881 of 5 stars	1.1	0.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.71	Moderate Buy	$58.60	46.54% Upside
CGON CG Oncology	3.08	Buy	$55.30	112.04% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	38.40% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside

Current Analyst Ratings Breakdown

Latest OPT, AGIO, CGON, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/28/2025	CGON CG Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$75.00 ➝ $75.00
4/28/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	63.46	N/A	N/A	$27.02 per share	1.48
CGON CG Oncology	$662K	3,002.94	N/A	N/A	$9.63 per share	2.71
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.90	N/A	N/A	$6.60 per share	4.31
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.56	N/A	N/A	1,798.26%	-2.75%	-2.52%	7/30/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	113.68	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest OPT, AGIO, CGON, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	N/A	N/A	N/A	$9.46 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	18.50	17.93
CGON CG Oncology	N/A	30.97	30.97
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
OPT Opthea	N/A	1.57	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CGON CG Oncology	26.56%
KNSA Kiniksa Pharmaceuticals International	53.95%
OPT Opthea	55.95%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
CGON CG Oncology	7.40%
KNSA Kiniksa Pharmaceuticals International	53.48%
OPT Opthea	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	55.43 million	Optionable
CGON CG Oncology	61	76.23 million	70.58 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable

OPT, AGIO, CGON, and KNSA Headlines

Recent News About These Companies

Opthea (NASDAQ:OPT) Stock Price Up 7.2% - Time to Buy?

July 4, 2025 | marketbeat.com

Opthea (NASDAQ:OPT) Shares Gap Up - Here's Why

July 3, 2025 | marketbeat.com

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected

July 2, 2025 | msn.com

Opthea Faces Leadership Changes Amidst Clinical Trial Setbacks

June 1, 2025 | tipranks.com

Biotech Dimerix lands $940m licensing deal for kidney drug sales

May 1, 2025 | afr.com

Phil King’s Regal successfully bets against Tesla, Nvidia

May 1, 2025 | afr.com

'No one is happy': Regal stockpickers face financial hit after Opthea blow up

April 21, 2025 | capitalbrief.comC

Regal’s King says his hedge funds will recover from March madness

April 16, 2025 | afr.com

Regal: Don’t catch the falling knife, wait for it to stick in the floor

April 16, 2025 | msn.com

Opthea to lay off approximately 65% of company

April 10, 2025 | ophthalmologytimes.comO

Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops

April 10, 2025 | fiercebiotech.comF

BELL POTTER SECURITIES Downgrades Opthea (CKDXF)

April 9, 2025 | msn.com

BELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)

April 9, 2025 | msn.com

ASX drops as US jumbo China tariff takes effect

April 9, 2025 | afr.com

Opthea Limited (CKDXF) was downgraded to a Sell Rating at Bell Potter

April 3, 2025 | markets.businessinsider.com

Phil King’s Regal writes Opthea to zero and backs off risky bets

April 2, 2025 | afr.com

Opthea Ends Development of Sozinibercept in Wet AMD

March 31, 2025 | marketwatch.com

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

March 31, 2025 | endpts.comE

Opthea terminates COAST trial, announces ShORe trial misses endpoint

March 31, 2025 | markets.businessinsider.com

Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail

March 31, 2025 | fiercebiotech.comF

Opthea discontinues development of sozinibercept in wet AMD

March 31, 2025 | healio.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Reddit Stock Ignites: Surge in Call Options Signals Big Bet
By Gabriel Osorio-Mazilli | June 24, 2025
View Reddit Stock Ignites: Surge in Call Options Signals Big Bet
Snowflake Hits 52-Week High—Options Traders Bet on Further Rally
By Gabriel Osorio-Mazilli | June 29, 2025
View Snowflake Hits 52-Week High—Options Traders Bet on Further Rally

OPT, AGIO, CGON, and KNSA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$39.99 +0.80 (+2.04%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$39.98 -0.01 (-0.04%)

As of 07:00 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CG Oncology NASDAQ:CGON

$26.08 +1.13 (+4.53%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$25.26 -0.82 (-3.16%)

As of 07:05 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.42 +0.33 (+1.17%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$28.42 +0.00 (+0.02%)

As of 07/16/2025 04:20 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 07/15/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time